Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough treatments for immune-mediated and oncological diseases. The company is pioneering first-in-class small molecule therapies that inhibit major regulators of cellular function through a single, powerful target, suppressing multiple disease drivers. KZR-616, a selective immunoproteasome inhibitor, is currently being evaluated in Phase 2 clinical trials for lupus nephritis, dermatomyositis, and polymyositis.